Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients with Acute Leukemia with and without Mixed-Lineage Leukemia (MLL)-Rearrangement (R) or Nucleophosmin 1 (NPM1) Mutation (m)
Publication
, Conference
Daver, N; Ikezoe, T; Watts, J; Hosono, N; Ogawa, Y; Miyazaki, Y; Erba, HP; Affinito, J; Brooks, E; Eguchi, K; Cai, H; Xu, B; Stoudemire, J ...
Published in: Blood
November 15, 2022
Duke Scholars
Published In
Blood
DOI
EISSN
1528-0020
ISSN
0006-4971
Publication Date
November 15, 2022
Volume
140
Issue
Supplement 1
Start / End Page
3371 / 3372
Publisher
American Society of Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Daver, N., Ikezoe, T., Watts, J., Hosono, N., Ogawa, Y., Miyazaki, Y., … Yuda, J. (2022). Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients with Acute Leukemia with and without Mixed-Lineage Leukemia (MLL)-Rearrangement (R) or Nucleophosmin 1 (NPM1) Mutation (m). In Blood (Vol. 140, pp. 3371–3372). American Society of Hematology. https://doi.org/10.1182/blood-2022-167674
Daver, Naval, Takayuki Ikezoe, Justin Watts, Naoko Hosono, Yoshiaki Ogawa, Yasushi Miyazaki, Harry P. Erba, et al. “Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients with Acute Leukemia with and without Mixed-Lineage Leukemia (MLL)-Rearrangement (R) or Nucleophosmin 1 (NPM1) Mutation (m).” In Blood, 140:3371–72. American Society of Hematology, 2022. https://doi.org/10.1182/blood-2022-167674.
Daver N, Ikezoe T, Watts J, Hosono N, Ogawa Y, Miyazaki Y, et al. Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients with Acute Leukemia with and without Mixed-Lineage Leukemia (MLL)-Rearrangement (R) or Nucleophosmin 1 (NPM1) Mutation (m). In: Blood. American Society of Hematology; 2022. p. 3371–2.
Daver, Naval, et al. “Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients with Acute Leukemia with and without Mixed-Lineage Leukemia (MLL)-Rearrangement (R) or Nucleophosmin 1 (NPM1) Mutation (m).” Blood, vol. 140, no. Supplement 1, American Society of Hematology, 2022, pp. 3371–72. Crossref, doi:10.1182/blood-2022-167674.
Daver N, Ikezoe T, Watts J, Hosono N, Ogawa Y, Miyazaki Y, Erba HP, Affinito J, Brooks E, Eguchi K, Cai H, Xu B, Stoudemire J, Hitron M, Watanabe A, Komarnitsky P, Yuda J. Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients with Acute Leukemia with and without Mixed-Lineage Leukemia (MLL)-Rearrangement (R) or Nucleophosmin 1 (NPM1) Mutation (m). Blood. American Society of Hematology; 2022. p. 3371–3372.
Published In
Blood
DOI
EISSN
1528-0020
ISSN
0006-4971
Publication Date
November 15, 2022
Volume
140
Issue
Supplement 1
Start / End Page
3371 / 3372
Publisher
American Society of Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology